[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 23 of about 23
1. Iitaka D, Ikoma H, Kawaguchi T, Murayama Y, Komatsu S, Shiozaki A, Kuriu Y, Nakanishi M, Ichikawa D, Fujiwara H, Okamoto K, Ochiai T, Kokuba Y, Sonoyama T, Konishi H, Yoshikawa T, Otsuji E: [A case report--locally advanced pancreatic adenocarcinoma was resected after chemotherapy]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2358-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Upper gastrointestinal endoscopy revealed circumferential stenosis in the fourth portion of the duodenum, while CT revealed a tumor with a diameter of 60 mm continuing as a single mass from the pancreatic body and tail to the fourth portion of the duodenum, and this was accompanied by findings that raised suspicions of circumferential invasion of the superior mesentric artery (SMA).
  • Based on these results and biopsy, the patient was diagnosed with pancreatic and SMA invasion of duodenal cancer that was considered to be unresectable.
  • The tumor response was PR and the images indicated the SMA invasion was disappeared.
  • In the surgical findings, the tumor continued as a single mass from the pancreatic body and tail to the third portion of the duodenum, and the surrounding area exhibited marked fibrosis.
  • We performed a pancreatic tail resection along with combined resection of third and fourth portions of the duodenum, transverse colon and splenic flexure, and left adrenal gland.
  • The case was diagnosed to be well-differentiated invasive ductal pancreatic cancer with duodenal invasion.
  • Cancer invasion was not observed in any of the stripped surfaces surrounding the pancreas.
  • In this case, the treatment was initially started by considering the case as one of duodenal cancer, but the final results of a pathological diagnosis revealed that it was pancreatic cancer.
  • However, either way, even though the case was unresectable before the chemotherapy performed for duodenal cancer was significantly effective for the pancreatic cancer.
  • [MeSH-minor] Adult. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Combinations. Duodenal Neoplasms / pathology. Duodenal Neoplasms / therapy. Humans. Male. Mesenteric Artery, Superior / pathology. Neoplasm Invasiveness. Oxonic Acid / administration & dosage. Taxoids / administration & dosage. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224572.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Drug Combinations; 0 / Taxoids; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 15H5577CQD / docetaxel; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


2. Qu X, Xiao D, Weber HC: Human gastrin-releasing peptide receptor mediates sustained CREB phosphorylation and transactivation in HuTu 80 duodenal cancer cells. FEBS Lett; 2002 Sep 11;527(1-3):109-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human gastrin-releasing peptide receptor mediates sustained CREB phosphorylation and transactivation in HuTu 80 duodenal cancer cells.
  • Here, we demonstrated hGRP-R activation stimulated sustained cyclic AMP response element binding protein (CREB) phosphorylation and transactivation in duodenal cancer cells through a protein kinase C and partially p38 mitogen-activated protein kinase-dependent pathway.
  • This novel signaling mechanism might be of importance for regulation of CREB-dependent gene expression in human cancer expressing functional hGRP-R.
  • [MeSH-major] Cyclic AMP Response Element-Binding Protein / metabolism. Duodenal Neoplasms / metabolism. Receptors, Bombesin / metabolism. Transcriptional Activation
  • [MeSH-minor] Bombesin / pharmacology. Calcium / metabolism. Cyclic AMP-Dependent Protein Kinases / metabolism. Enzyme Inhibitors / pharmacology. Humans. Imidazoles / pharmacology. Mitogen-Activated Protein Kinase 1 / metabolism. Mitogen-Activated Protein Kinase 3. Mitogen-Activated Protein Kinases / antagonists & inhibitors. Mitogen-Activated Protein Kinases / metabolism. Phosphorylation / drug effects. Protein Kinase C / metabolism. Pyridines / pharmacology. Recombinant Fusion Proteins / drug effects. Recombinant Fusion Proteins / genetics. Recombinant Fusion Proteins / metabolism. Serine / metabolism. Transcription, Genetic. Tumor Cells, Cultured. p38 Mitogen-Activated Protein Kinases

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • Guide to Pharmacology. gene/protein/disease-specific - BB2 receptor - data and references .
  • Hazardous Substances Data Bank. L-SERINE .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12220644.001).
  • [ISSN] 0014-5793
  • [Journal-full-title] FEBS letters
  • [ISO-abbreviation] FEBS Lett.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK 02722
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cyclic AMP Response Element-Binding Protein; 0 / Enzyme Inhibitors; 0 / Imidazoles; 0 / Pyridines; 0 / Receptors, Bombesin; 0 / Recombinant Fusion Proteins; 0 / SB 203580; 452VLY9402 / Serine; EC 2.7.11.11 / Cyclic AMP-Dependent Protein Kinases; EC 2.7.11.13 / Protein Kinase C; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; PX9AZU7QPK / Bombesin; SY7Q814VUP / Calcium
  •  go-up   go-down


3. Half E, Bercovich D, Rozen P: Familial adenomatous polyposis. Orphanet J Rare Dis; 2009;4:22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • FAP has an incidence at birth of about 1/8,300, it manifests equally in both sexes, and accounts for less than 1% of colorectal cancer (CRC) cases.
  • Most patients are asymptomatic for years until the adenomas are large and numerous, and cause rectal bleeding or even anemia, or cancer develops.
  • A less aggressive variant of FAP, attenuated FAP (AFAP), is characterized by fewer colorectal adenomatous polyps (usually 10 to 100), later age of adenoma appearance and a lower cancer risk.
  • Most patients (~70%) have a family history of colorectal polyps and cancer.
  • Diagnosis is based on a suggestive family history, clinical findings, and large bowel endoscopy or full colonoscopy.
  • Whenever possible, the clinical diagnosis should be confirmed by genetic testing.
  • Cancer prevention and maintaining a good quality of life are the main goals of management and regular and systematic follow-up and supportive care should be offered to all patients.
  • By the late teens or early twenties, colorectal cancer prophylactic surgery is advocated.
  • Duodenal cancer and desmoids are the two main causes of mortality after total colectomy, they need to be identified early and treated.
  • Upper endoscopy is necessary for surveillance to reduce the risk of ampullary and duodenal cancer.
  • Adjunctive therapy with celecoxib has been approved by the US Food and Drug Administration and the European Medicines Agency in patients with FAP.
  • [MeSH-major] Adenomatous Polyposis Coli / diagnosis. Adenomatous Polyposis Coli / pathology
  • [MeSH-minor] Animals. Female. Humans. Male

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • SciCrunch. KEGG: Data: Disease Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Gastroenterol. 1993 Dec;17(4):343-7, discussion 347-8 [8308223.001]
  • [Cites] Hum Mutat. 1994;3(2):121-5 [8199592.001]
  • [Cites] Hum Genet. 1994 Nov;94(5):543-8 [7959691.001]
  • [Cites] N Engl J Med. 1995 Mar 30;332(13):839-47 [7661930.001]
  • [Cites] Ann Surg. 1995 Aug;222(2):120-7 [7639579.001]
  • [Cites] Am Fam Physician. 1995 Sep 15;52(4):1210 [7668210.001]
  • [Cites] Surgery. 1996 Jun;119(6):615-23 [8650601.001]
  • [Cites] Br J Surg. 1996 Jun;83(6):769-70 [8696735.001]
  • [Cites] Br J Surg. 1996 Jul;83(7):885-92 [8813770.001]
  • [Cites] J Med Genet. 1996 Jul;33(7):540-3 [8818937.001]
  • [Cites] Br J Surg. 1996 Nov;83(11):1578-80 [9014679.001]
  • [Cites] AJR Am J Roentgenol. 1997 Aug;169(2):465-72 [9242755.001]
  • [Cites] Ann Surg. 1997 Oct;226(4):514-9; discussion 519-21 [9351719.001]
  • [Cites] Arch Dis Child. 1997 Nov;77(5):431-5 [9487968.001]
  • [Cites] Am J Hum Genet. 1998 Mar;62(3):736-7 [9497250.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Apr;8(4 Pt 2):353-60 [10207640.001]
  • [Cites] Am J Hum Genet. 1999 Sep;65(3):902-9 [10441594.001]
  • [Cites] Nucleic Acids Res. 1999 Sep 15;27(18):3638-44 [10471731.001]
  • [Cites] Fam Cancer. 2006;5(3):213-20 [16998666.001]
  • [Cites] Fam Cancer. 2006;5(3):227-35 [16998668.001]
  • [Cites] Fam Cancer. 2006;5(3):241-60; discussion 261-2 [16998670.001]
  • [Cites] Fam Cancer. 2006;5(3):275-85; discussion 287-8 [16998673.001]
  • [Cites] Gastrointest Endosc. 2006 Oct;64(4):530-7 [16996344.001]
  • [Cites] Genet Med. 2006 Nov;8(11):697-703 [17108761.001]
  • [Cites] Reprod Biomed Online. 2006 Nov;13(5):707-11 [17169185.001]
  • [Cites] Mol Hum Reprod. 2007 Feb;13(2):95-101 [17114207.001]
  • [Cites] Am J Gastroenterol. 2007 Jun;102(6):1284-90 [17355417.001]
  • [Cites] Hum Mutat. 2007 Oct;28(10):985-92 [17486639.001]
  • [Cites] Genet Test. 2007 Fall;11(3):315-20 [17949294.001]
  • [Cites] Gastrointest Endosc. 2008 Jan;67(1):61-7 [18155426.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Feb;6(2):180-5 [18237868.001]
  • [Cites] Fam Cancer. 2008;7(1):27-39 [17999161.001]
  • [Cites] Gut. 2008 May;57(5):704-13 [18194984.001]
  • [Cites] Curr Protoc Hum Genet. 2006 Aug;Chapter 10:Unit 10.8 [18428386.001]
  • [Cites] Endoscopy. 2008 May;40(5):437-42 [18398783.001]
  • [Cites] Am J Surg. 2008 Jun;195(6):741-8 [18436175.001]
  • [Cites] Clin Chem. 2008 Jul;54(7):1132-40 [18487285.001]
  • [Cites] Pathol Res Pract. 2008;204(7):479-90 [18538487.001]
  • [Cites] Ann Surg Oncol. 2008 Sep;15(9):2439-50 [18612695.001]
  • [Cites] Eur J Cancer. 2008 Nov;44(16):2404-10 [18706807.001]
  • [Cites] Gastrointest Endosc. 2008 Nov;68(5):911-9 [18561922.001]
  • [Cites] Gastroenterology. 2008 Dec;135(6):2014-8 [19013464.001]
  • [Cites] J Pediatr. 1999 Sep;135(3):390-5 [10484811.001]
  • [Cites] Endoscopy. 1999 Aug;31(6):412-6 [10494676.001]
  • [Cites] Am J Hum Genet. 1955 Sep;7(3):236-63 [13258558.001]
  • [Cites] Dis Colon Rectum. 1959 Sep-Oct;2:465-8 [13839882.001]
  • [Cites] Genet Test. 2004 Winter;8(4):421-30 [15684875.001]
  • [Cites] N Engl J Med. 2005 Mar 17;352(11):1092-102 [15713943.001]
  • [Cites] Am J Med Genet A. 2005 Apr 15;134A(2):212-4 [15690400.001]
  • [Cites] Gastroenterology. 2005 Apr;128(4):1077-80 [15825088.001]
  • [Cites] Am J Gastroenterol. 2005 Jul;100(7):1498-502 [15984971.001]
  • [Cites] Dis Colon Rectum. 2005 Aug;48(8):1528-34 [15906134.001]
  • [Cites] Biochem Soc Trans. 2005 Aug;33(Pt 4):679-83 [16042573.001]
  • [Cites] Am J Med Genet A. 2006 Feb 1;140(3):200-4 [16411234.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):312-4 [16492921.001]
  • [Cites] Br J Surg. 2006 Apr;93(4):407-17 [16511903.001]
  • [Cites] Int J Cancer. 2006 Aug 15;119(4):807-14 [16557584.001]
  • [Cites] Gut. 1999 Dec;45(6):829-33 [10562580.001]
  • [Cites] Nucleic Acids Res. 2000 Mar 15;28(6):1355-64 [10684930.001]
  • [Cites] J Clin Oncol. 2000 May;18(9):1967-79 [10784639.001]
  • [Cites] N Engl J Med. 2000 Jun 29;342(26):1946-52 [10874062.001]
  • [Cites] Dis Colon Rectum. 2000 Jul;43(7):893-8; discussion 898-902 [10910233.001]
  • [Cites] Am J Pathol. 2000 Sep;157(3):747-54 [10980114.001]
  • [Cites] Gastroenterology. 2000 Dec;119(6):1454-60 [11113066.001]
  • [Cites] Ann Surg. 2001 Mar;233(3):360-4 [11224623.001]
  • [Cites] Arch Ophthalmol. 2001 Apr;119(4):597-602 [11296028.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 May 1;50(1):121-5 [11316554.001]
  • [Cites] Gastroenterology. 2001 Jul;121(1):195-7 [11438508.001]
  • [Cites] J Wound Ostomy Continence Nurs. 2001 Jul;28(4):184-9 [11452254.001]
  • [Cites] Nat Genet. 2002 Feb;30(2):227-32 [11818965.001]
  • [Cites] Gastroenterology. 2002 Mar;122(3):641-5 [11874996.001]
  • [Cites] N Engl J Med. 2002 Apr 4;346(14):1054-9 [11932472.001]
  • [Cites] Gut. 2002 May;50(5):636-41 [11950808.001]
  • [Cites] J Gastrointest Surg. 2002 Jan-Feb;6(1):82-7 [11986022.001]
  • [Cites] Hum Mutat. 2002 Jun;19(6):664 [12007223.001]
  • [Cites] Gut. 2002 Sep;51(3):446-9 [12171972.001]
  • [Cites] J Clin Microbiol. 2002 Oct;40(10):3565-71 [12354847.001]
  • [Cites] Dis Colon Rectum. 2002 Nov;45(11):1496-502 [12432298.001]
  • [Cites] Br J Surg. 2003 Feb;90(2):227-31 [12555301.001]
  • [Cites] N Engl J Med. 2003 Feb 27;348(9):791-9 [12606733.001]
  • [Cites] Dis Colon Rectum. 2003 Apr;46(4):481-5 [12682541.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1752-5 [12702556.001]
  • [Cites] Gastroenterology. 2003 May;124(6):1574-94 [12761718.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):3891-3 [12873979.001]
  • [Cites] Dis Colon Rectum. 2003 Oct;46(10):1418-23; discussion 1422-3 [14530685.001]
  • [Cites] Fam Cancer. 2001;1(2):75-82 [14574001.001]
  • [Cites] Fam Cancer. 2003;2(1):43-55 [14574166.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4756-60 [14581346.001]
  • [Cites] Dig Dis Sci. 2003 Oct;48(10):1998-2002 [14627347.001]
  • [Cites] Genet Test. 2003 Fall;7(3):189-94 [14641994.001]
  • [Cites] Cancer. 2004 Feb 1;100(3):612-20 [14745880.001]
  • [Cites] Gut. 2004 Mar;53(3):381-6 [14960520.001]
  • [Cites] Hum Mutat. 2003 Jun;21(6):655-6 [14961559.001]
  • [Cites] Int J Cancer. 2004 May 1;109(5):680-4 [14999774.001]
  • [Cites] Oncogene. 2004 Sep 2;23(40):6820-2 [15273732.001]
  • [Cites] Gastroenterology. 2004 Sep;127(3):838-44 [15362039.001]
  • [Cites] Acta Chir Scand. 1975;141(3):228-37 [1166747.001]
  • [Cites] Am J Hum Genet. 1988 Feb;42(2):290-6 [3422541.001]
  • [Cites] Lancet. 1989 Sep 30;2(8666):783-5 [2571019.001]
  • [Cites] Ann Med. 1989 Aug;21(4):299-307 [2551351.001]
  • [Cites] Gastroenterology. 1991 Jun;100(6):1658-64 [1673441.001]
  • [Cites] Cell. 1991 Aug 9;66(3):589-600 [1651174.001]
  • [Cites] Science. 1991 Aug 9;253(5020):665-9 [1651563.001]
  • [Cites] Nature. 1992 Sep 17;359(6392):235-7 [1528264.001]
  • [Cites] N Engl J Med. 1993 May 6;328(18):1313-6 [8385741.001]
  • [Cites] Am J Hum Genet. 1993 Jul;53(1):33-45 [8317496.001]
  • (PMID = 19822006.001).
  • [ISSN] 1750-1172
  • [Journal-full-title] Orphanet journal of rare diseases
  • [ISO-abbreviation] Orphanet J Rare Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 114
  • [Other-IDs] NLM/ PMC2772987
  •  go-up   go-down


Advertisement
4. Matsuzu K, Ike H, Cho H, Ashida A, Fujikawa H, Saito B, Hayashi T, Fujii K, Kojima Y, Narui K, Fujii Y, Makino T, Wada N, Rino Y, Masuda M: [Long survival of a case of unresected duodenal cancer treated by S-1 before and after duodenojejunostomy]. Gan To Kagaku Ryoho; 2009 Sep;36(9):1573-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long survival of a case of unresected duodenal cancer treated by S-1 before and after duodenojejunostomy].
  • Detailed examination revealed a duodenal cancer of the ascending limbs.
  • Duodenography and endoscopy showed duodenal obstruction, and she underwent surgery.
  • The combination of S-1 administration and bypass operation provides a useful alternative for the treatment of unresectable duodenal cancer with stenosis.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Duodenal Neoplasms / therapy. Duodenostomy. Jejunostomy. Oxonic Acid / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Combined Modality Therapy. Drug Combinations. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19755837.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


5. Watanabe C, Okubo Y, Ohi T, Koga M, Abe H, Tawara K, Tsuboi N, Hayashi T: A case of dermatomyositis associated with mechanic's hand. J Dermatol; 2000 Nov;27(11):711-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 67-year-old man was referred to the Department of Internal Medicine at Tokyo Medical University with interstitial pneumonia in July 1999.
  • Based on these findings, the patient was given a diagnosis of dermatomyositis associated with mechanic's hand.
  • A systemic examination confirmed interstitial pneumonia and carcinoma of the duodenal papilla.
  • Mechanic's hand is a type of dermatitis associated with myopathy first reported by Stahl et al. in patients with collagen disease.
  • [MeSH-major] Dermatomyositis / diagnosis. Hand Dermatoses / diagnosis
  • [MeSH-minor] Adenocarcinoma / complications. Aged. Ampulla of Vater. Diagnosis, Differential. Duodenal Neoplasms / complications. Humans. Lung Diseases, Interstitial / complications. Male. Pneumonia / complications

  • Genetic Alliance. consumer health - Dermatomyositis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11138537.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 10
  •  go-up   go-down


6. Haag M, Magada ON, Claassen N, Böhmer LH, Kruger MC: Omega-3 fatty acids modulate ATPases involved in duodenal Ca absorption. Prostaglandins Leukot Essent Fatty Acids; 2003 Jun;68(6):423-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Omega-3 fatty acids modulate ATPases involved in duodenal Ca absorption.
  • Dietary supplementation with fish oil that contains omega-3 polyunsaturated fatty acids has been shown to enhance bone density as well as duodenal calcium uptake in rats.
  • The present in vitro study was undertaken to test the effect of omega-3 fatty acids on ATPase activity in isolated basolateral membranes from rat duodenal enterocytes.
  • Ca-ATPase in calmodulin-stripped membranes was activated in a biphasic manner by docosahexanoic acid (DHA) (10-30 microg/ml) but not by eicosapentanoic acid (EPA).
  • Omega-3 fatty acids are thus involved in multiple signalling effects that effect ATPases in BLM.
  • [MeSH-major] Apyrase / metabolism. Calcium / metabolism. Duodenum / metabolism. Fatty Acids, Omega-3 / pharmacology
  • [MeSH-minor] Absorption / drug effects. Animals. Cell Membrane / drug effects. Cell Membrane / enzymology. Dose-Response Relationship, Drug. Enterocytes / drug effects. Enterocytes / enzymology. Enterocytes / metabolism. Enzyme Inhibitors / pharmacology. Male. Naphthalenes / pharmacology. Protein Kinase C / antagonists & inhibitors. Protein Kinase C / metabolism. Rats

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12798663.001).
  • [ISSN] 0952-3278
  • [Journal-full-title] Prostaglandins, leukotrienes, and essential fatty acids
  • [ISO-abbreviation] Prostaglandins Leukot. Essent. Fatty Acids
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Fatty Acids, Omega-3; 0 / Naphthalenes; 0 / calphostin complex; EC 2.7.11.13 / Protein Kinase C; EC 3.6.1.5 / Apyrase; SY7Q814VUP / Calcium
  •  go-up   go-down


7. Arnold SM, Rinehart JJ, Tsakalozou E, Eckardt JR, Fields SZ, Shelton BJ, DeSimone PA, Kee BK, Moscow JA, Leggas M: A phase I study of 7-t-butyldimethylsilyl-10-hydroxycamptothecin in adult patients with refractory or metastatic solid malignancies. Clin Cancer Res; 2010 Jan 15;16(2):673-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No drug accumulation was observed on day 4.
  • A prolonged partial response was observed in one subject with non-small cell lung cancer.
  • Stable disease was noted in patients with small cell lung cancer, non-small cell lung cancer, and duodenal cancer.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1995 Apr 13;332(15):1004-14 [7885406.001]
  • [Cites] Expert Opin Ther Pat. 2009 May;19(5):555-74 [19441934.001]
  • [Cites] Cancer Res. 1996 May 1;56(9):2112-5 [8616858.001]
  • [Cites] J Biol Chem. 1998 Apr 10;273(15):8719-26 [9535849.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):685-96 [10080615.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;43(6):454-60 [10321504.001]
  • [Cites] J Med Chem. 1999 Aug 12;42(16):3018-22 [10447944.001]
  • [Cites] Lung Cancer. 2005 Jun;48(3):399-407 [15893009.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Nov 21;844(1):15-22 [16860004.001]
  • [Cites] Ann Oncol. 2007 Mar;18(3):561-8 [17150998.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] J Med Chem. 2000 Oct 19;43(21):3970-80 [11052802.001]
  • [Cites] Clin Pharmacol Ther. 2000 Oct;68(4):356-66 [11061575.001]
  • [Cites] Ann N Y Acad Sci. 2000;922:112-21 [11193887.001]
  • [Cites] J Control Release. 2001 Jul 6;74(1-3):325-33 [11489514.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):405-12 [11839656.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2202-9 [12114421.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15387-92 [12426403.001]
  • [Cites] Bioorg Med Chem. 2003 Feb 6;11(3):451-8 [12517440.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Jun;53(6):527-32 [14997342.001]
  • [Cites] J Biol Chem. 1985 Nov 25;260(27):14873-8 [2997227.001]
  • [Cites] Cancer Res. 1988 Apr 1;48(7):1722-6 [2832051.001]
  • [Cites] J Med Chem. 1989 Mar;32(3):715-20 [2537428.001]
  • [Cites] Biochemistry. 1993 May 25;32(20):5352-64 [8499440.001]
  • [Cites] J Med Chem. 1993 Aug 20;36(17):2580-2 [8355258.001]
  • [Cites] Anal Biochem. 1993 Jul;212(1):285-7 [8368506.001]
  • [Cites] Biochemistry. 1994 Aug 30;33(34):10325-36 [8068669.001]
  • [Cites] Comb Chem High Throughput Screen. 2007 Jul;10(6):486-92 [17896945.001]
  • [Cites] Clin Cancer Res. 2009 Jan 1;15(1):374-81 [19118068.001]
  • [Cites] Biochemistry. 1995 Oct 24;34(42):13722-8 [7577964.001]
  • (PMID = 20068096.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-123867; United States / NCI NIH HHS / CA / R21 CA123867-01A1; United States / NCI NIH HHS / CA / CA123867-01A1; United States / NCI NIH HHS / CA / R21 CA123867-02; United States / NCI NIH HHS / CA / CA123867-02; United States / NCI NIH HHS / CA / R21 CA123867
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organosilicon Compounds; 3YEA04NV6H / 7-tert-butyldimethylsilyl-10-hydroxycamptothecin; XT3Z54Z28A / Camptothecin
  • [Other-IDs] NLM/ NIHMS159503; NLM/ PMC2831464
  •  go-up   go-down


8. Ishida M, Niguma T, Kimura T, Mimura T, Tsutsui N: [A case report of successful control of liver metastasis from duodenal cancer with combined S-1 and docetaxel chemotherapy]. Gan To Kagaku Ryoho; 2007 Sep;34(9):1477-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report of successful control of liver metastasis from duodenal cancer with combined S-1 and docetaxel chemotherapy].
  • A 70-year-old man with abdominal pain and anemia was diagnosed with duodenal cancer upon upper gastrointestinal endoscopy and biopsy.
  • Pathological findings were duodenal cancer, T 4 SI (Panc) N0P0V0A0H0.
  • Combined S-1 and docetaxel chemotherapy is known to be effective for esophageal cancer, gastric cancer and other digestive cancer, as well as for duodenal cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Duodenal Neoplasms / pathology. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary
  • [MeSH-minor] Aged. Antineoplastic Agents / administration & dosage. Drug Combinations. Humans. Male. Oxonic Acid / administration & dosage. Taxoids / administration & dosage. Tegafur / administration & dosage

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17876150.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Combinations; 0 / Taxoids; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 15H5577CQD / docetaxel; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


9. Kashiwagi H, Spigelman AD: Gastroduodenal lesions in familial adenomatous polyposis. Surg Today; 2000;30(8):675-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prophylactic colectomy is generally recommended for patients with familial adenomatous polyposis (FAP) who are inevitably affected with large bowel cancer.
  • Duodenal adenomas are found in patients with FAP and the adenoma-carcinoma sequence exists in the FAP duodenum, suggesting that treatment of duodenal polyps might be beneficial.
  • Several methods of treatment for duodenal lesions in patients with FAP have been reported, but the current treatment options are not ideal.
  • The nonsteroid anti-inflammatory drugs, sulindac and aspirin, are used for chemoprevention, while recently developed cyclooxygenase-2 inhibitors may be of some use in the future.
  • Endoscopic polypectomy has been attempted for duodenal polyps and open surgical polypectomy has proven to be effective for selected patients.
  • New methods of duodenal resection, such as pancreas-preserving duodenectomy and pylorus-preserving pancreaticoduodenectomy, might be considered for severe duodenal polyposis; however, because prophylactic duodenal surgery has been considered too aggressive, surveillance duodenoscopy is usually performed to detect duodenal cancer at an early stage.
  • [MeSH-major] Adenoma / etiology. Adenomatous Polyposis Coli / complications. Adenomatous Polyposis Coli / surgery. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Carcinoma / etiology. Colectomy. Duodenal Neoplasms / etiology

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1974 Sep;34(3):745-54 [4852134.001]
  • [Cites] Ann Surg. 1993 Feb;217(2):101-8 [8382467.001]
  • [Cites] Gastrointest Endosc. 1996 Sep;44(3):305-8 [8885351.001]
  • [Cites] J Clin Pathol. 1990 Sep;43(9):738-43 [2170464.001]
  • [Cites] Cancer Res. 1990 Nov 15;50(22):7166-73 [1977514.001]
  • [Cites] Gut. 1987 Mar;28(3):306-14 [3032754.001]
  • [Cites] Dig Dis Sci. 1987 May;32(5):459-65 [3032535.001]
  • [Cites] Gastroenterology. 1997 Aug;113(2):659-63 [9247488.001]
  • [Cites] Br J Surg. 1999 Feb;86(2):189-93 [10100785.001]
  • [Cites] Gastroenterology. 1985 Nov;89(5):1021-5 [4043660.001]
  • [Cites] Am J Hum Genet. 1998 Jun;62(6):1290-301 [9585611.001]
  • [Cites] Ann Surg. 1977 May;185(5):565-73 [856075.001]
  • [Cites] Gut. 1983 Apr;24(4):333-9 [6832628.001]
  • [Cites] Gastroenterology. 1984 Feb;86(2):295-301 [6690356.001]
  • [Cites] Int J Colorectal Dis. 1995;10(1):43-6 [7745323.001]
  • [Cites] Carcinogenesis. 1991 Sep;12(9):1727-32 [1654227.001]
  • [Cites] Cancer. 1995 Dec 15;76(12):2427-33 [8625067.001]
  • [Cites] Gut. 1997 Oct;41(4):518-21 [9391252.001]
  • [Cites] Gastroenterology. 1992 Dec;103(6):1725-31 [1333425.001]
  • [Cites] Eur J Cancer. 1995 Jul-Aug;31A(7-8):1160-5 [7577013.001]
  • [Cites] Dis Colon Rectum. 1992 Oct;35(10):996-8 [1327683.001]
  • [Cites] Int J Colorectal Dis. 1992 Dec;7(4):177-83 [1338090.001]
  • [Cites] Dis Colon Rectum. 1992 Dec;35(12):1170-3 [1335405.001]
  • [Cites] JAMA. 1962 Mar 31;179:1026-8 [14477413.001]
  • [Cites] Cancer Res. 1992 Jul 15;52(14):3965-71 [1319835.001]
  • [Cites] Gastroenterology. 1992 Jun;102(6):1980-2 [1316858.001]
  • [Cites] Surg Oncol. 1992 Oct;1(5):357-61 [1341271.001]
  • [Cites] J Clin Gastroenterol. 1996 Apr;22(3):237-41 [8724267.001]
  • [Cites] Br J Surg. 1993 Dec;80(12):1618-9 [8298943.001]
  • [Cites] Oncogene. 1995 May 4;10(9):1875-8 [7753564.001]
  • [Cites] Gastroenterology. 1989 May;96(5 Pt 1):1301-6 [2703115.001]
  • [Cites] Surg Endosc. 1996 Apr;10(4):418-21 [8661792.001]
  • [Cites] Hum Genet. 1997 May;99(5):653-7 [9150735.001]
  • [Cites] Gut. 1981 May;22(5):363-7 [7250748.001]
  • [Cites] Lancet. 1988 May 21;1(8595):1149-51 [2896968.001]
  • [Cites] Am J Gastroenterol. 1998 Sep;93(9):1566-8 [9732948.001]
  • [Cites] Cancer Res. 1995 Jul 15;55(14):3165-70 [7606737.001]
  • [Cites] Surg Gynecol Obstet. 1980 Jun;150(6):822-6 [7376043.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):3011-20 [8187091.001]
  • [Cites] Br J Surg. 1993 Aug;80(8):1027-9 [8402056.001]
  • [Cites] Cancer Res. 1991 Jun 1;51(11):2874-8 [1851662.001]
  • [Cites] Am J Physiol. 1992 Aug;263(2 Pt 2):F181-91 [1324603.001]
  • [Cites] J Clin Pathol. 1994 Aug;47(8):709-10 [7962621.001]
  • [Cites] Endoscopy. 1995 Jan;27(1):6-11 [7601038.001]
  • [Cites] Gut. 1995 Feb;36(2):251-4 [7883225.001]
  • [Cites] Dis Colon Rectum. 1993 Nov;36(11):1059-62 [8223060.001]
  • [Cites] Carcinogenesis. 1992 Apr;13(4):731-5 [1315631.001]
  • [Cites] Dis Colon Rectum. 1985 Sep;28(9):664-8 [4053908.001]
  • [Cites] Am J Surg. 1996 Jan;171(1):136-40; discussion 140-1 [8554128.001]
  • [Cites] Br J Surg. 1998 May;85(5):665-8 [9635818.001]
  • [Cites] Cancer. 1988 Feb 1;61(3):605-11 [3338026.001]
  • [Cites] J Med Genet. 1996 Apr;33(4):268-73 [8730279.001]
  • [Cites] Br J Surg. 1997 Jun;84(6):826-9 [9189100.001]
  • [Cites] Eur J Cancer. 1995 Jul-Aug;31A(7-8):1149-53 [7577011.001]
  • [Cites] Gastroenterology. 1977 Nov;73(5):1086-92 [908488.001]
  • [Cites] Cell. 1996 Nov 29;87(5):803-9 [8945508.001]
  • [Cites] Lancet. 1994 Dec 3;344(8936):1582 [7983986.001]
  • [Cites] J Am Coll Surg. 1994 Oct;179(4):462-4 [7921398.001]
  • [Cites] Dig Dis Sci. 1989 Feb;34(2):167-70 [2536604.001]
  • [Cites] Lancet. 1989 Sep 30;2(8666):783-5 [2571019.001]
  • [Cites] Surgery. 1995 Mar;117(3):254-9 [7878529.001]
  • [Cites] Eur J Gastroenterol Hepatol. 1996 Dec;8(12):1201-6 [8980941.001]
  • [Cites] Dis Colon Rectum. 1985 Feb;28(2):90-3 [3971812.001]
  • [Cites] Gastrointest Endosc. 1993 Mar-Apr;39(2):127-31 [8495831.001]
  • [Cites] Br J Surg. 1996 Feb;83(2):225-8 [8689171.001]
  • [Cites] J R Soc Med. 1994 Nov;87(11):704-6 [7837198.001]
  • [Cites] Cancer. 1992 Oct 1;70(7):1847-56 [1326395.001]
  • (PMID = 10955728.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal
  • [Number-of-references] 74
  •  go-up   go-down


10. Song Y, Kato S, Fleet JC: Vitamin D receptor (VDR) knockout mice reveal VDR-independent regulation of intestinal calcium absorption and ECaC2 and calbindin D9k mRNA. J Nutr; 2003 Feb;133(2):374-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To study the role of calbindin D(9k) (CaBP) and epithelial calcium channel ECaC2 in intestinal calcium (Ca) absorption, vitamin D receptor knockout (KO) and wild-type (WT) mice were fed either 0.5% Ca or a 2.0% Ca rescue diet starting at 21 d of age.
  • Ca absorption and parameters involved in this process were measured at 60 or 90 d of age.
  • Compared with WT, KO mice fed the 0.5% Ca diet had higher plasma parathyroid hormone (PTH) and 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)], and lower plasma Ca and insulin-like growth factor-I (IGF-I).
  • Duodenal Ca absorption (% Ca absorbed) in KO mice was reduced 71% relative to WT mice and was associated with 55% lower CaBP mRNA, 47% lower CaBP protein and 95% lower ECaC2 mRNA levels.
  • Compared with WT mice, the percentage of Ca absorbed in KO mice fed the 0.5% Ca diet was inappropriately low for the level of duodenal CaBP.
  • The 2% Ca rescue diet normalized plasma Ca, prevented osteomalacia, increased growth and plasma IGF-I levels, but did not normalize plasma PTH or 1,25(OH)(2)D(3) in KO mice.
  • In addition, the relationship between CaBP protein and the percentage of Ca absorbed was normalized, whereas ECaC2 mRNA fell to near zero.
  • Our data demonstrate that higher CaBP levels do not ensure high rates of duodenal Ca absorption and that transcellular Ca absorption can occur even when ECaC2 gene expression is very low.
  • In addition, our data suggest that the 2% Ca diet promotes a vitamin D receptor-independent anabolic effect on bone formation and calcium absorption, leading to improved calcium balance even in the presence of high PTH levels.

  • MedlinePlus Health Information. consumer health - Calcium.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12566470.001).
  • [ISSN] 0022-3166
  • [Journal-full-title] The Journal of nutrition
  • [ISO-abbreviation] J. Nutr.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK054111-04; United States / NIDDK NIH HHS / DK / R01 DK054111; United States / NIDDK NIH HHS / DK / R01 DK054111-04; United States / NIDDK NIH HHS / DK / R01-DK54111
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calbindins; 0 / Calcium, Dietary; 0 / Parathyroid Hormone; 0 / Receptors, Calcitriol; 0 / S100 Calcium Binding Protein G; 0 / S100g protein, mouse
  •  go-up   go-down


11. Iso Y, Sawada T, Tagaya N, Kato M, Rokkaku K, Shimoda M, Kita J, Kubota K: Pancreatic juice leakage is a risk factor for deep mycosis after pancreatic surgery. Surg Today; 2009;39(4):326-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Their diagnoses consisted of cancer of the papilla of Vater (n = 9), pancreatic head cancer (n = 20), pancreatic tail cancer (n = 3), bile duct cancer (n = 17), duodenal cancer (n = 3), and others (n = 15).
  • An antifungal drug (Micafungin; 75 mg per day) was given to G1 patients.
  • All the G1 patients were treated with the antifungal drug for 7.8 days.
  • Therefore, an early diagnosis of DM and the initiation of antifungal treatment are necessary for the improving prognosis.

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Yeast Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg. 1993 Dec;166(6):617-9; discussion 619-20 [8273839.001]
  • [Cites] Ann Surg. 1990 Oct;212(4):496-510; discussion 511-2 [2222015.001]
  • [Cites] Diabetes. 1975 Oct;24(10):944-57 [170155.001]
  • [Cites] Surg Today. 2007;37(10):860-6 [17879035.001]
  • [Cites] Clin Infect Dis. 1992 Apr;14(4):952-4 [1576294.001]
  • [Cites] J Clin Invest. 1968 Sep;47(9):1973-99 [5675423.001]
  • [Cites] Eur J Clin Microbiol. 1983 Apr;2(2):122-8 [6861734.001]
  • [Cites] J Pediatr Surg. 1991 Aug;26(8):904-6; discussion 907 [1919981.001]
  • [Cites] Surgery. 2005 Jul;138(1):8-13 [16003309.001]
  • [Cites] Surg Clin North Am. 1996 Oct;76(5):1159-73 [8841370.001]
  • [Cites] J Clin Microbiol. 1986 Oct;24(4):542-7 [3533975.001]
  • [Cites] Arch Surg. 1992 Aug;127(8):945-9; discussion 949-50 [1353671.001]
  • (PMID = 19319641.001).
  • [ISSN] 1436-2813
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] RFM9X3LJ49 / Bilirubin
  •  go-up   go-down


12. National Toxicology Program: Toxicology and carcinogenesis studies of sodium dichromate dihydrate (Cas No. 7789-12-0) in F344/N rats and B6C3F1 mice (drinking water studies). Natl Toxicol Program Tech Rep Ser; 2008 Jul;(546):1-192
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incidences of squamous cell carcinoma in the oral mucosa of 516 mg/L male and female rats were significantly greater than those in the controls.
  • The incidences of squamous cell papilloma or squamous cell carcinoma (combined) of the oral mucosa or tongue of 516 mg/L male and female rats were significantly greater than those in the controls.
  • Exposure concentration-related nonneoplastic liver lesions were observed in males and females exposed to 57.3 mg/L or greater.
  • Increased incidences of histiocytic cellular infiltration also occurred in the small intestine (duodenum), mesenteric lymph node, and pancreatic lymph node of males and/or females exposed to 57.3 mg/L or greater.
  • The incidences of neoplasms of the small intestine (duodenum, jejunum, or ileum) were increased in exposed groups of male and female mice.
  • The incidences of adenoma of the duodenum in 257.4 mg/L males and 172 and 516 mg/L females were significantly greater than those in the controls.
  • The incidence of carcinoma of the duodenum was significantly increased in 516 mg/L females.
  • When the incidences of adenoma and carcinoma were combined for all sites of the small intestine, the incidences were significantly increased in 85.7 and 257.4 mg/L males and 172 and 516 mg/L females compared to those in the controls.
  • The incidences of diffuse epithelial hyperplasia were significantly increased in the duodenum of all exposed groups of male and female mice.
  • The incidences of histiocytic cellular infiltration were significantly increased in the duodenum of 85.7 and 257.4 mg/L males and in 172 and 516 mg/L females.
  • There was clear evidence of carcinogenic activity of sodium dichromate dihydrate in male and female B6C3F1 mice based on increased incidences of neoplasms of the small intestine (duodenum, jejunum, or ileum).
  • Exposure to sodium dichromate dihydrate resulted in histiocytic cellular infiltration in the liver, small intestine, and pancreatic and mesenteric lymph nodes of rats and mice and diffuse epithelial hyperplasia in the small intestine of male and female mice.
  • [MeSH-minor] Administration, Oral. Animals. Female. Intestinal Neoplasms / chemically induced. Intestinal Neoplasms / pathology. Intestine, Small / drug effects. Intestine, Small / pathology. Liver / drug effects. Liver / pathology. Lymph Nodes / drug effects. Lymph Nodes / pathology. Male. Mice. Mice, Inbred Strains. Mouth Neoplasms / chemically induced. Mouth Neoplasms / pathology. Rats. Rats, Inbred F344. Water Supply

  • Hazardous Substances Data Bank. SODIUM DICHROMATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18716633.001).
  • [ISSN] 0888-8051
  • [Journal-full-title] National Toxicology Program technical report series
  • [ISO-abbreviation] Natl Toxicol Program Tech Rep Ser
  • [Language] eng
  • [Publication-type] Journal Article; Technical Report
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromates; 0 / Water Pollutants, Chemical; C9G6VY6ZZ4 / sodium bichromate
  •  go-up   go-down


13. Taniguchi M, Ookubo K, Ootsuka M, Akitake H, Maekawa T, Yoshioka S, Hama N, Kashiwazaki M, Tsujie M, Konishi M, Ebisui C, Fujimoto T: [A case of successful control of recurrent duodenal carcinoma receiving paclitaxel]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2315-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of successful control of recurrent duodenal carcinoma receiving paclitaxel].
  • We have experienced a case of successful control of recurrent duodenal carcinoma receiving paclitaxel chemotherapy.
  • A 61-year-old woman with epigastralgia was diagnosed with pyloric gastric carcinoma upon upper gastrointestinal endoscopy and biopsy.
  • However, at the resected organ, the lesion was on the duodenum.
  • And 13a, 13b, 12a, p lymph nodes were dissected for duodenal carcinoma.
  • Recurrence of the duodenal carcinoma was diagnosed in February 2007, and S-1 administration was begun.
  • Paclitaxel chemotherapy is effective for duodenal cancer.
  • [MeSH-major] Duodenal Neoplasms / drug therapy. Paclitaxel / therapeutic use
  • [MeSH-minor] Antimetabolites, Antineoplastic / therapeutic use. Carnitine O-Palmitoyltransferase / therapeutic use. Drug Combinations. Female. Humans. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Oxonic Acid / therapeutic use. Tegafur / therapeutic use

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037407.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; EC 2.3.1.21 / Carnitine O-Palmitoyltransferase; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


14. Yang CX, Xu MY, Liu FY, Yang DX, Wang SZ: L-365,260 reversed effect of sincalide against morphine on electrical and mechanical activities of rat duodenum in vitro. Acta Pharmacol Sin; 2002 Jul;23(7):582-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] L-365,260 reversed effect of sincalide against morphine on electrical and mechanical activities of rat duodenum in vitro.
  • METHODS: The electrical and mechanical activities of rat duodenum in vitro were recorded simultaneously.
  • RESULTS: Acetylcholine (ACh, 300 nmol/L) increased the spike potential amplitude (SPA) and the number (SPN) of rat duodenum in vitro, followed by an increase of duodenal contraction amplitudes (CA).
  • The SPA, SPN, and CA of duodenum in vitro were not obviously affected by injection of morphine (330 nmol/L), but it could selectively inhibit the potentiation of ACh.
  • After administration of CCK-8 (0.7 nmol/L), the SPA, SPN, and CA of duodenal segment did not exhibit obvious changes.
  • But CCK-8 could selectively antagonize the effects of morphine, ie, the SPA and SPN were increased again, followed by an increase of CA.
  • CONCLUSION: CCK-8 could selectively antagonize the effect of morphine which inhibited the potentiation of ACh on duodenal activities in vitro.
  • [MeSH-major] Benzodiazepinones / pharmacology. Duodenum / physiology. Morphine / antagonists & inhibitors. Phenylurea Compounds / pharmacology. Receptor, Cholecystokinin B / antagonists & inhibitors. Sincalide / pharmacology
  • [MeSH-minor] Acetylcholine / pharmacology. Action Potentials / drug effects. Animals. Female. In Vitro Techniques. Male. Muscle Contraction / drug effects. Muscle, Smooth / drug effects. Rats. Rats, Wistar

  • Hazardous Substances Data Bank. MORPHINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12100748.001).
  • [ISSN] 1671-4083
  • [Journal-full-title] Acta pharmacologica Sinica
  • [ISO-abbreviation] Acta Pharmacol. Sin.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Benzodiazepinones; 0 / Phenylurea Compounds; 0 / Receptor, Cholecystokinin B; 118101-09-0 / L 365260; 76I7G6D29C / Morphine; M03GIQ7Z6P / Sincalide; N9YNS0M02X / Acetylcholine
  •  go-up   go-down


15. Shitara K, Munakata M, Sakata Y, Ishii E, Kondo M, Wada R: [A case of duodenal carcinoma with massive peritoneal carcinomatosis complicating a pulmonary embolism]. Gan To Kagaku Ryoho; 2006 Nov;33(11):1661-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of duodenal carcinoma with massive peritoneal carcinomatosis complicating a pulmonary embolism].
  • The incidence of venous thromboembolism in cancer patients is reportedly around 15%, and a pulmonary embolism is an important cause of morbidity and mortality.
  • We present a case of duodenal carcinoma with peritoneal carcinomatosis complicated by a pulmonary embolism.
  • [MeSH-major] Adenocarcinoma / secondary. Duodenal Neoplasms / pathology. Peritoneal Neoplasms / secondary. Pulmonary Embolism / drug therapy. Pulmonary Embolism / etiology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Combinations. Drug Therapy, Combination. Female. Heparin / administration & dosage. Humans. Middle Aged. Oxonic Acid / administration & dosage. Quality of Life. Taxoids / administration & dosage. Tegafur / administration & dosage. Warfarin / administration & dosage

  • Genetic Alliance. consumer health - Embolism.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Pulmonary Embolism.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. WARFARIN .
  • Hazardous Substances Data Bank. HEPARIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17108737.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Taxoids; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 15H5577CQD / docetaxel; 5Q7ZVV76EI / Warfarin; 5VT6420TIG / Oxonic Acid; 9005-49-6 / Heparin
  •  go-up   go-down


16. Johnson JC, DiSario JA, Grady WM: Surveillance and Treatment of Periampullary and Duodenal Adenomas in Familial Adenomatous Polyposis. Curr Treat Options Gastroenterol; 2004 Apr;7(2):79-89
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surveillance and Treatment of Periampullary and Duodenal Adenomas in Familial Adenomatous Polyposis.
  • Patients with familial adenomatous polyposis (FAP) have a cumulative lifetime risk of over 90% for developing duodenal adenomas, which are the precursor lesions for duodenal adenocarcinoma.
  • Consequently, these patients have a 5% to 10% lifetime risk of periampullary or duodenal adenocarcinoma, making this the leading cause of cancer death in FAP patients who have had prophylactic colectomies.
  • The increased relative risk of duodenal carcinoma in FAP patients and the poor outcomes associated with the treatment of advanced duodenal cancer have led to the development of prevention strategies for this cancer in the setting of FAP.
  • It is generally accepted that surveillance for duodenal adenomas and adenocarcinomas should be included in the management of patients with FAP, although there are few data from clinical trials that demonstrate the effectiveness of surveillance strategies or chemoprevention for the prevention of death from duodenal cancer.
  • Prospective case series have shown that endoscopic surveillance with endoscopic or surgical treatment of high-risk lesions in the duodenal or periampullary region can be performed with successful removal of the at-risk lesion(s).
  • Patients with denser polyposis or larger adenomas are recommended to undergo examination every 6 to 12 months because of their increased risk of developing duodenal adenocarcinoma.
  • Nonsteroidal anti-inflammatory drug therapy with sulindac, a nonselective cyclooxygenase (COX) inhibitor, or celecoxib, a COX-2 selective inhibitor, may be of benefit after the development of duodenal polyposis by inducing the regression or stabilization of the polyposis, although there is limited evidence from randomized, controlled trials to support its routine use.
  • Almost all cases of adenocarcinoma occur in patients with advanced polyposis (Spigelman stage IV disease), and approximately 33% of this group will go on to develop adenocarcinoma if left untreated.
  • The most definitive procedure for reducing the risk of adenocarcinoma is surgical resection of the ampulla and/or duodenum.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gut. 2002 Oct;51 Suppl 5:V21-7 [12221036.001]
  • [Cites] J Clin Pathol. 1990 Sep;43(9):738-43 [2170464.001]
  • [Cites] Lancet. 1995 Apr 1;345(8953):855-6 [7898240.001]
  • [Cites] Br J Surg. 1996 Dec;83(12):1763-6 [9038563.001]
  • [Cites] Ann Surg Oncol. 2000 Aug;7(7):484-9 [10947015.001]
  • [Cites] J Gastrointest Surg. 2002 Jan-Feb;6(1):82-7 [11986022.001]
  • [Cites] J Gastrointest Surg. 2001 Jan-Feb;5(1):21-6 [11309644.001]
  • [Cites] Int J Colorectal Dis. 1995;10(1):43-6 [7745323.001]
  • [Cites] Carcinogenesis. 1997 Oct;18(10):1863-5 [9363991.001]
  • [Cites] Gut. 2002 Jun;50(6):857-60 [12010890.001]
  • [Cites] Gastrointest Endosc. 2002 Mar;55(3):390-6 [11868015.001]
  • [Cites] Eur J Cancer. 1995 Jul-Aug;31A(7-8):1160-5 [7577013.001]
  • [Cites] Gastroenterology. 2001 Nov;121(5):1127-35 [11677205.001]
  • [Cites] Dis Colon Rectum. 1992 Dec;35(12):1170-3 [1335405.001]
  • [Cites] Gastroenterology. 1992 Jun;102(6):1980-2 [1316858.001]
  • [Cites] J Clin Gastroenterol. 1996 Apr;22(3):237-41 [8724267.001]
  • [Cites] Br J Surg. 1993 Dec;80(12):1618-9 [8298943.001]
  • [Cites] Am J Med Genet. 1980;6(3):205-19 [6999900.001]
  • [Cites] Gut. 1995 Jan;36(1):67-75 [7890239.001]
  • [Cites] Gastrointest Endosc. 1999 Mar;49(3 Pt 1):358-64 [10049420.001]
  • [Cites] N Engl J Med. 2000 Jun 29;342(26):1946-52 [10874062.001]
  • [Cites] Lancet. 1988 May 21;1(8595):1149-51 [2896968.001]
  • [Cites] Gut. 1996 Apr;38(4):578-81 [8707091.001]
  • [Cites] Gastrointest Endosc. 2002 Mar;55(3):342-7 [11868006.001]
  • [Cites] J Natl Cancer Inst. 1989 Sep 6;81(17):1290-7 [2549261.001]
  • [Cites] J Gastrointest Surg. 2002 Nov-Dec;6(6):831-7; discussion 837 [12504221.001]
  • [Cites] Br J Surg. 1993 Aug;80(8):1027-9 [8402056.001]
  • [Cites] J Clin Gastroenterol. 1993 Dec;17(4):343-7, discussion 347-8 [8308223.001]
  • [Cites] Gastroenterology. 2003 Nov;125(5):1462-9 [14598262.001]
  • [Cites] Gastroenterology. 2000 Sep;119(3):837-53 [10982778.001]
  • [Cites] Cancer. 1999 Oct 15;86(8):1414-20 [10526267.001]
  • [Cites] Gastrointest Endosc. 2001 Aug;54(2):202-8 [11474391.001]
  • [Cites] Br J Surg. 1998 May;85(5):665-8 [9635818.001]
  • [Cites] Eur J Surg. 2002;168(2):74-7 [12113274.001]
  • [Cites] Cell. 1996 Nov 29;87(5):803-9 [8945508.001]
  • [Cites] Gastrointest Endosc. 1991 May-Jun;37(3):383-93 [2070995.001]
  • [Cites] Int J Colorectal Dis. 1997;12(1):14-8 [9112144.001]
  • [Cites] Br J Surg. 1998 Jun;85(6):742-50 [9667698.001]
  • [Cites] Lancet. 1989 Sep 30;2(8666):783-5 [2571019.001]
  • [Cites] Gut. 1997 Jun;40(6):716-9 [9245923.001]
  • [Cites] Gut. 2002 May;50(5):636-41 [11950808.001]
  • [Cites] Endoscopy. 2001 Apr;33(4):345-7 [11315897.001]
  • [Cites] Cancer. 1982 Oct 1;50(7):1434-9 [7049351.001]
  • [Cites] Am J Gastroenterol. 2001 Jan;96(1):101-6 [11197237.001]
  • [Cites] Yonsei Med J. 2000 Apr;41(2):213-8 [10817022.001]
  • [Cites] Gastrointest Endosc. 1993 Mar-Apr;39(2):127-31 [8495831.001]
  • [Cites] J Gastrointest Surg. 2002 Sep-Oct;6(5):671-5 [12399055.001]
  • [Cites] Am J Surg. 1996 Jan;171(1):131-4; discussion 134-5 [8554127.001]
  • [Cites] Ann Surg. 1998 Sep;228(3):429-38 [9742926.001]
  • [Cites] Endoscopy. 1994 Mar;26(3):308-10 [8076551.001]
  • [Cites] Br J Surg. 1993 Apr;80(4):499-501 [8388307.001]
  • [Cites] Endoscopy. 1999 Aug;31(6):412-6 [10494676.001]
  • [Cites] Ann Surg. 1993 May;217(5):430-5; discussion 435-8 [8098202.001]
  • [Cites] Dis Colon Rectum. 1999 Dec;42(12):1533-6 [10613470.001]
  • (PMID = 15010021.001).
  • [ISSN] 1092-8472
  • [Journal-full-title] Current treatment options in gastroenterology
  • [ISO-abbreviation] Curr Treat Options Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Song Y, Fleet JC: Intestinal resistance to 1,25 dihydroxyvitamin D in mice heterozygous for the vitamin D receptor knockout allele. Endocrinology; 2007 Mar;148(3):1396-402
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We tested the hypothesis that low vitamin D receptor (VDR) level causes intestinal vitamin D resistance and intestinal calcium (Ca) malabsorption.
  • To do so, we examined vitamin D regulated duodenal Ca absorption and gene expression [transient receptor potential channel, vallinoid subfamily member 6 (TRPV6), 24-hydroxylase, calbindin D(9k) (CaBP) mRNA, and CaBP protein] in wild-type mice and mice with reduced tissue VDR levels [i.e. heterozygotes for the VDR gene knockout (HT)].
  • Induction of 24-hydroxylase mRNA levels by 1,25 dihydroxyvitamin D(3) [1,25(OH)(2) D(3)] injection was significantly reduced in the duodenum and kidney of HT mice in both time-course and dose-response experiments.
  • TRPV6 and CaBP mRNA levels in duodenum were significantly induced after 1,25(OH)(2) D(3) injection, but there was no difference in response between wild-type and HT mice.
  • In contrast, duodenal TRPV6 and CaBP mRNA were not higher in HT mice fed the low-calcium diet.
  • However, the response of duodenal Ca absorption and CaBP protein to increasing 1,25(OH)(2) D(3) levels was blunted by 40% in HT mice.
  • Our data show that low VDR levels lead to resistance of intestinal Ca absorption to 1,25(OH)(2) D(3), and this resistance may be due to a role for the VDR (and VDR level) in the translation of CaBP.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 1,25-DIHYDROXYCHOLECALCIFEROL .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1996 Nov 22;271(47):29715-21 [8939905.001]
  • [Cites] Endocrinology. 2000 Jul;141(7):2301-8 [10875229.001]
  • [Cites] Nat Genet. 1997 Aug;16(4):391-6 [9241280.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Sep 2;94(18):9831-5 [9275211.001]
  • [Cites] Mech Ageing Dev. 1997 Dec 15;99(2):109-22 [9483486.001]
  • [Cites] Arch Biochem Biophys. 1998 Apr 15;352(2):159-64 [9587402.001]
  • [Cites] Endocrinology. 1998 Sep;139(9):3843-8 [9724038.001]
  • [Cites] Endocrinology. 1999 Jan;140(1):280-5 [9886836.001]
  • [Cites] Am J Physiol. 1999 Apr;276(4 Pt 1):G958-64 [10198340.001]
  • [Cites] J Biol Chem. 1999 Aug 6;274(32):22739-46 [10428857.001]
  • [Cites] Comp Biochem Physiol A Mol Integr Physiol. 2004 Oct;139(2):133-41 [15528161.001]
  • [Cites] J Bone Miner Res. 2005 Mar;20(3):447-54 [15746989.001]
  • [Cites] J Mol Biol. 2005 Jul 1;350(1):65-77 [15919092.001]
  • [Cites] Ann Intern Med. 2000 Mar 7;132(5):345-53 [10691584.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Nov;85(11):4023-7 [11095427.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Nov 19;278(2):326-32 [11097838.001]
  • [Cites] J Bone Miner Res. 2001 Apr;16(4):615-24 [11315989.001]
  • [Cites] Bone. 2001 Jul;29(1):35-41 [11472889.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13324-9 [11687634.001]
  • [Cites] Mol Endocrinol. 2002 Jul;16(7):1524-37 [12089348.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2002 Sep;283(3):G618-25 [12181175.001]
  • [Cites] J Nutr. 2003 Feb;133(2):374-80 [12566470.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9733-7 [12900504.001]
  • [Cites] Endocrinology. 2003 Sep;144(9):3885-94 [12933662.001]
  • [Cites] Osteoporos Int. 2004 Jan;15(1):27-31 [14598024.001]
  • [Cites] Eur J Clin Nutr. 2004 Feb;58(2):264-9 [14749746.001]
  • [Cites] J Nutr. 2004 Aug;134(8):1857-61 [15284366.001]
  • [Cites] Am J Clin Nutr. 2004 Oct;80(4):998-1002 [15447911.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Nov;287(5):G943-53 [15217781.001]
  • [Cites] Proc Natl Acad Sci U S A. 1971 Jun;68(6):1286-8 [4331086.001]
  • [Cites] J Nucl Med. 1973 Oct;14(10):760-2 [4743584.001]
  • [Cites] Arch Biochem Biophys. 1979 Feb;192(2):466-73 [107861.001]
  • [Cites] Am J Physiol. 1983 Mar;244(3):C303-7 [6829752.001]
  • [Cites] Am J Physiol. 1985 Jul;249(1 Pt 1):G108-12 [4014460.001]
  • [Cites] Am J Physiol. 1986 May;250(5 Pt 1):G561-9 [2939728.001]
  • [Cites] Endocrinology. 1986 Dec;119(6):2476-83 [3780535.001]
  • [Cites] J Biol Chem. 1987 Dec 5;262(34):16553-7 [2445747.001]
  • [Cites] Endocrinology. 1990 Feb;126(2):1053-7 [2153518.001]
  • [Cites] J Clin Endocrinol Metab. 1990 Nov;71(5):1288-93 [2229286.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jan 15;89(2):603-7 [1309950.001]
  • [Cites] Gastroenterology. 1992 Mar;102(3):886-94 [1311274.001]
  • [Cites] J Nutr. 1992 Mar;122(3 Suppl):678-82 [1542030.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Jul;75(1):176-82 [1320048.001]
  • [Cites] Mol Endocrinol. 2006 Feb;20(2):291-301 [16179380.001]
  • [Cites] Mol Endocrinol. 2006 Jun;20(6):1447-61 [16574738.001]
  • [Cites] J Trace Elem Med Biol. 2006;20(2):73-81 [16785046.001]
  • [Cites] Bone. 1997 Mar;20(3):237-43 [9071474.001]
  • (PMID = 17110426.001).
  • [ISSN] 0013-7227
  • [Journal-full-title] Endocrinology
  • [ISO-abbreviation] Endocrinology
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK054111-10; United States / NIDDK NIH HHS / DK / R01 DK054111; United States / NIDDK NIH HHS / DK / DK 054111; United States / NIDDK NIH HHS / DK / R01 DK054111-10
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calbindins; 0 / Receptors, Calcitriol; 0 / S100 Calcium Binding Protein G; FXC9231JVH / Calcitriol; SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ NIHMS82630; NLM/ PMC2617756
  •  go-up   go-down


18. Chen PW, Kroog GS: Alterations in receptor expression or agonist concentration change the pathways gastrin-releasing peptide receptor uses to regulate extracellular signal-regulated kinase. Mol Pharmacol; 2004 Dec;66(6):1625-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we demonstrate that gastrin-releasing peptide receptor (GRPr) regulates ERK through multiple pathways in a single cell type depending upon receptor expression and agonist concentration.
  • Furthermore, a GRPr-expressing human duodenal cancer cell line showed differential sensitivity to GF 109203X throughout BN-induced ERK activation, indicating that GRPr may activate ERK via multiple pathways in cells expressing endogenous GRPr.
  • [MeSH-minor] 3T3 Cells. Animals. Bombesin / pharmacology. Cell Line. Enzyme Activation / drug effects. Enzyme Inhibitors / pharmacology. Humans. Indoles / pharmacology. Maleimides / pharmacology. Mice. Microscopy, Confocal. Protein Transport. Tetradecanoylphorbol Acetate / pharmacology

  • Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15361544.001).
  • [ISSN] 0026-895X
  • [Journal-full-title] Molecular pharmacology
  • [ISO-abbreviation] Mol. Pharmacol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1K22-CA098102
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Indoles; 0 / Maleimides; 0 / Receptors, Bombesin; 133052-90-1 / bisindolylmaleimide I; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; NI40JAQ945 / Tetradecanoylphorbol Acetate; PX9AZU7QPK / Bombesin
  •  go-up   go-down


19. Egawa T, Ohashi M, Ito Y, Hayashi S, Doi M, Nagashima A: [A partial response to combined S-1 and CDDP chemotherapy enabling a curative resection in a patient with locally advanced duodenal cancer]. Gan To Kagaku Ryoho; 2008 Nov;35(12):2083-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A partial response to combined S-1 and CDDP chemotherapy enabling a curative resection in a patient with locally advanced duodenal cancer].
  • CT revealed a primary duodenal tumor with bulky lymph node metastases.
  • Gastrofiberscopy revealed a primary duodenal tumor located the second portion.
  • Six months after the operation, the patient was doing well and showed no signs of recurrence of the cancer.
  • This S-1/CDDP combination chemotherapy was therefore considered to be suitable as neo-adjuvant chemotherapy because it permitted the patient to subsequently undergo a curative resection, and thereby achieving a survival benefit for locally advanced duodenal cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Duodenal Neoplasms / drug therapy. Duodenal Neoplasms / pathology. Oxonic Acid / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Chemotherapy, Adjuvant. Drug Combinations. Duodenoscopy. Humans. Male. Middle Aged. Neoplasm Staging. Remission Induction. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106531.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


20. Ohuchi S, Kotanagi H, Kamata S, Sakusabe M, Seki H, Sawata T, Kumagai Y: [A case of peritoneal dissemination of postoperative primary duodenal cancer successfully treated by TS-1 therapy]. Gan To Kagaku Ryoho; 2005 Aug;32(8):1179-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of peritoneal dissemination of postoperative primary duodenal cancer successfully treated by TS-1 therapy].
  • An endoscopic examination detected a type 2 tumor of the descending limb of the duodenum.
  • With a diagnosis of adenocarcinoma based on the biopsy finding, the patient was subjected to surgery.
  • Laparotomy revealed the presence of a duodenal tumor disseminating to the omentum at the site where the transverse colon is attached.
  • Upon consultation with the patient, a regimen of 80 mg/day of TS-1 given for 4 weeks followed by 2 weeks of a drug-free period was initiated.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Duodenal Neoplasms / drug therapy. Neoplasm Seeding. Omentum / pathology. Oxonic Acid / therapeutic use. Pyridines / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Colectomy. Drug Combinations. Humans. Liver / pathology. Male. Middle Aged. Pancreaticoduodenectomy

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16121925.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


21. Katoh M, Katoh M: Comparative integromics on Eph family. Int J Oncol; 2006 May;28(5):1243-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human EPHA7 mRNA was expressed in embryonic stem (ES) cells, neural tissues, duodenal cancer and parathyroid tumors, while mouse Epha7 mRNA was expressed in fertilized egg, Rathke's pouche, visual cortex, pituitary gland, other neural tissues, pancreas, lung tumors and mammary tumors.
  • D6S1056 microsatellite marker within EPHA7 gene is deleted in prostate cancer.
  • EPHA7 is a target of systems medicine, especially in the fields of regenerative medicine and oncology.
  • [MeSH-minor] Animals. Base Sequence. Cattle. Cloning, Molecular. Conserved Sequence. Genome, Human. Humans. Ligands. Molecular Sequence Data. Multigene Family. Pan troglodytes. Promoter Regions, Genetic. Sequence Alignment. Sequence Homology, Nucleic Acid


22. Peters WH, van Schaik A, Peters JH, van Goor H: Oxidised- and total non-protein bound glutathione and related thiols in gallbladder bile of patients with various gastrointestinal disorders. BMC Gastroenterol; 2007;7:7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Gallbladder bile was obtained after cholecystectomy from 30 patients who were operated for pancreatic cancer, duodenal cancer, chronic pancreatitis or cholecystolithiasis.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cholecystolithiasis / metabolism. Duodenal Neoplasms / metabolism. Female. Humans. Male. Middle Aged. Oxidative Stress / physiology. Pancreatic Neoplasms / metabolism. Pancreatitis, Chronic / metabolism. Pilot Projects

  • MedlinePlus Health Information. consumer health - Digestive Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Obstet Gynecol. 2001 Feb;97(2):272-6 [11165594.001]
  • [Cites] Clin Chim Acta. 2003 Jul 1;333(1):19-39 [12809732.001]
  • [Cites] J Clin Invest. 1984 Jan;73(1):124-33 [6690473.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2006 Jul;291(1):G1-7 [16500922.001]
  • [Cites] Toxicol Appl Pharmacol. 1988 May;93(3):351-9 [2897139.001]
  • [Cites] Semin Liver Dis. 1998;18(4):313-29 [9875551.001]
  • [Cites] Curr Drug Targets Immune Endocr Metabol Disord. 2005 Jun;5(2):153-61 [16089347.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Mar;83(5):1246-50 [2869485.001]
  • (PMID = 17319949.001).
  • [ISSN] 1471-230X
  • [Journal-full-title] BMC gastroenterology
  • [ISO-abbreviation] BMC Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Sulfhydryl Compounds; GAN16C9B8O / Glutathione
  • [Other-IDs] NLM/ PMC1805502
  •  go-up   go-down


23. Robinson A, Clark WF: A case report of gemcitabine treatment for duodenal cancer: the good (a sustained response) and the bad (life threatening refractory thrombotic thrombocytopenic purpura). J Gastrointest Cancer; 2010 Mar;41(1):71-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case report of gemcitabine treatment for duodenal cancer: the good (a sustained response) and the bad (life threatening refractory thrombotic thrombocytopenic purpura).
  • INTRODUCTION: Adenocarcinoma of the duodenum is a rare cancer and not submitted to the type of clinical trials that guide chemotherapy treatments in other gastrointestinal malignancies.
  • CASE REPORT: This case demonstrates the potential use for gemcitabine, a chemotherapy typically used in pancreas and biliary tract tumors, in this difficult to treat disease as this patient had a partial response to single agent gemcitabine.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / adverse effects. Deoxycytidine / analogs & derivatives. Duodenal Neoplasms / drug therapy. Purpura, Thrombotic Thrombocytopenic / chemically induced
  • [MeSH-minor] Female. Humans. Middle Aged. Omentum / pathology. Pancreas / pathology. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1997 Dec 17;89(24):1895-6 [9414181.001]
  • [Cites] Am J Hematol. 2006 Dec;81(12):895-900 [16888787.001]
  • [Cites] Br J Haematol. 2005 Sep;130(5):768-76 [16115135.001]
  • [Cites] Ann Hematol. 2005 Feb;84(2):110-4 [15340761.001]
  • [Cites] N Engl J Med. 2008 Oct 23;359(17):1757-65 [18946061.001]
  • [Cites] Lancet Oncol. 2007 Jul;8(7):634-41 [17613425.001]
  • [Cites] Curr Opin Hematol. 2008 Sep;15(5):445-50 [18695366.001]
  • [Cites] Am J Clin Oncol. 2006 Jun;29(3):225-31 [16755174.001]
  • [Cites] Cancer. 1999 Dec 15;86(12):2693-706 [10594865.001]
  • [Cites] Int J Hematol. 2004 Jul;80(1):94-6 [15293577.001]
  • [Cites] Anticancer Drugs. 1998 Mar;9(3):191-201 [9625429.001]
  • [Cites] Am J Gastroenterol. 2006 Dec;101(12):2826-32 [17026561.001]
  • (PMID = 19967470.001).
  • [ISSN] 1941-6636
  • [Journal-full-title] Journal of gastrointestinal cancer
  • [ISO-abbreviation] J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down






Advertisement